IGF-1 LR3 vs BPC-157 + TB-500
IGF-1 LR3 and BPC-157 + TB-500 come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do IGF-1 LR3 and BPC-157 + TB-500 differ?
IGF-1 LR3 (Recombinant IGF-1 analog polypeptide) is catalogued under longevity & cellular research; BPC-157 + TB-500 (Co-formulated two-peptide research blend) is catalogued under recovery & gut research. Verve lists 5 reported research applications for IGF-1 LR3 and 5 for BPC-157 + TB-500. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | IGF-1 LR3 | BPC-157 + TB-500 |
|---|---|---|
| compound class | Recombinant IGF-1 analog polypeptide | Co-formulated two-peptide research blend |
| research area | longevity & cellular | recovery & gut |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | co-formulated blend |
| catalog sizes | 1mg · 2x 1mg | 20mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | available | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $93.49 | $171.49 |
| availability | out of stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is IGF-1 LR3 and what is BPC-157 + TB-500?
IGF-1 LR3 is classified as Recombinant IGF-1 analog polypeptide; BPC-157 + TB-500 as Co-formulated two-peptide research blend. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
IGF-1 LR3
Recombinant IGF-1 analog polypeptide
IGF-1 LR3 is Long R3 insulin-like growth factor 1, a recombinant analog of human IGF-1 carrying an arginine substitution at position 3 and a 13-residue N-terminal extension. Those two modifications are what define it: they substantially reduce its affinity for the insulin-like growth factor binding proteins (IGFBPs) that sequester native IGF-1 in culture systems.
full IGF-1 LR3 profile →BPC-157 + TB-500
Co-formulated two-peptide research blend
BPC-157 + TB-500 is a co-formulated research blend that combines two of the most frequently cited reference peptides in tissue-repair literature, BPC-157 / TB-500, in a single vial. BPC-157 is a synthetic pentadecapeptide derived from a partial sequence identified in human gastric juice; TB-500 is a synthetic 43-amino-acid peptide corresponding to an active fragment of thymosin beta-4, a naturally-occurring actin-binding protein.
full BPC-157 + TB-500 profile →Which research models is each compound studied in?
IGF-1 LR3 sits in longevity & cellular research and BPC-157 + TB-500 in recovery & gut research, so their listed models largely do not intersect. The table lists 5 reported research applications for IGF-1 LR3 and 5 for BPC-157 + TB-500. Rows are per compound, not equivalences.
| IGF-1 LR3 — reported research applications | BPC-157 + TB-500 — reported research applications |
|---|---|
| IGF-1 receptor binding and signal-transduction research | Multi-compound tissue-repair research models |
| PI3K/Akt and MAPK pathway research in cellular models | Cell-migration and wound-healing research |
| Cell-culture media supplementation for proliferation research | Angiogenesis and vascular-signaling research |
| IGFBP interaction and free-ligand availability studies | Actin-regulation and cytoskeletal research |
| Comparative analog research against native IGF-1 | Comparative research on blended versus single-peptide preparations |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for IGF-1 LR3 and BPC-157 + TB-500?
IGF-1 LR3 is listed from $93.49 and BPC-157 + TB-500 from $171.49. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| IGF-1 LR3 | 1mg | $93.49 | out of stock |
| IGF-1 LR3 | 2x 1mg | $171.49 | out of stock |
| BPC-157 + TB-500 | 20mg | $171.49 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about IGF-1 LR3 and BPC-157 + TB-500
What is IGF-1 LR3?
IGF-1 LR3 is Long R3 insulin-like growth factor 1, a recombinant analog of human IGF-1 with an arginine substitution at position 3 and an N-terminal extension. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
How does IGF-1 LR3 differ from native IGF-1?
Its structural modifications reduce affinity for IGF binding proteins, so more of the ligand remains unbound in culture systems. Researchers use that property to control free-ligand availability in in-vitro models.
What is BPC-157 + TB-500?
BPC-157 + TB-500 is a co-formulated research blend of two well-characterized reference peptides, BPC-157 / TB-500, supplied in one vial. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is the BPC-157 / TB-500 blend studied for in research?
It is used in multi-compound cellular models covering tissue repair, cell migration, angiogenesis, and actin regulation, where both peptides are studied together. Verve makes no health claims.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.